- Home
- GCTS vs RIGL Comparison
GCTS vs RIGL Comparison
Compare GCTS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | RIGL |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GCTS | RIGL |
|---|---|---|
| Price | $1.24 | $44.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $43.20 |
| AVG Volume (30 Days) | 144.3K | ★ 562.5K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $3,893,000.00 | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $1,205.88 | $0.22 |
| P/E Ratio | ★ N/A | $6.71 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $0.90 | $14.63 |
| 52 Week High | $2.76 | $52.24 |
Technical Indicators
Market Signals| Indicator | GCTS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 54.78 |
| Support Level | $1.29 | $40.52 |
| Resistance Level | $1.49 | $43.58 |
| Average True Range (ATR) | 0.09 | 2.59 |
| MACD | -0.02 | -0.65 |
| Stochastic Oscillator | 3.85 | 44.02 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.